Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MYLK | Q15746 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770715 | 0.95 | CXCR2 (0.50) | CXCR2MAPTUSP2PKLRALDH1A1 | |
| SCHEMBL6564215 | 0.87 | CXCR2 (0.44) | CXCR2LMNACNR1CCR6 | |
| SCHEMBL6562315 | 0.86 | CXCR2 (0.45) | CXCR2ALDH1A1MEN1KMT2ACNR1 | |
| SCHEMBL13205457 | 0.86 | ALDH1A1 (0.45) | CXCR2USP2ALDH1A1MEN1KMT2A | |
| SCHEMBL17293683 | 0.85 | TSHR (0.46) | CXCR2USP2ALDH1A1MEN1CYP3A4 | |
| SCHEMBL1563469 | 0.82 | CXCR2 (0.54) | CXCR2MEN1KMT2ACCR6 | |
| SCHEMBL6562108 | 0.82 | CCR6 (0.41) | CXCR2CNR1CCR6 | |
| SCHEMBL6563361 | 0.82 | POLB (0.44) | MAPTUSP2MAPK1MEN1KMT2A | |
| SCHEMBL6562111 | 0.82 | CCR6 (0.41) | CXCR2CYP3A4KMT2ACNR1CCR6 | |
| SCHEMBL17293877 | 0.81 | ATM (0.43) | CXCR2ALDH1A1MAPK1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256157-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| EP-1272175-B1 | N,N'-DIARYL GUANIDINES AS IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20090281110-A1 | Method of Treatment | SMITHKLINE BEECHAM CORPORATION | 2009-11-12 | — | — | US | disclosed |
| US-20090170871-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | disclosed |
| EP-1351933-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060084641-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-04-20 | — | — | US | disclosed |
| EP-1351933-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1272175-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040048897-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
| US-6680317-B2 | N-(PHENYL)-N*-(2-HYDROXY-3-AMINOSULFONYLPHENYL)GUANIDINE DERIVATIVES; CHEMOKINE INHIBITORS; RESPIRATORY, CARDIOVASCULAR, RHEUMATIC, BRAIN, AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-01-20 | — | — | US | disclosed |
| US-20030216375-A1 | Il-8 receptor anatagonists | GLAXOSMITHKLINE LLC | 2003-11-20 | — | — | US | disclosed |
| CN-1452483-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2003-10-29 | — | — | CN | disclosed |
| EP-1351933-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1272175-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002057230-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2001072960-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256157-A1 | METHOD OF TREATMENT | CFTR, CTH, TST | CXCR2 794/4885MAPT 4780/4885USP2 42/4885 |
| US-20030216375-A1 | Il-8 receptor anatagonists | CXCL8, CCR8, IL1R1 | CXCR2 28/4885MAPT 2200/4885USP2 4521/4885 |
| US-20040048897-A1 | Il-8 receptor antagonists | CXCL8, CCR8, TLR8 | CXCR2 11/4885MAPT 3239/4885USP2 3113/4885 |
| US-20090281110-A1 | Method of Treatment | ESR2, CTH, SULT2A1 | CXCR2 2176/4885MAPT 3380/4885USP2 60/4885 |
| US-20060084641-A1 | IL-8 receptor antagonists | CXCL8, CCR8, TLR8 | CXCR2 11/4885MAPT 3239/4885USP2 3113/4885 |
| US-20090170871-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885MAPT 2222/4885USP2 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.